Model Selection Made Easy: Understanding Lung Cancer Models in One Article

Lung cancer, as one of the malignant tumors with the highest incidence and mortality worldwide, faces insurmountable barriers in its diagnosis and treatment. High individual heterogeneity, a complex and dynamically changing tumor microenvironment (TME), and rapidly emerging drug resistance during treatment collectively constitute enormous challenges for basic research and clinical translation.
· High Heterogeneity: An Obstacle to Precision Therapy
Tumor cells exhibit significant individual differences in gene expression and phenotype. Different patients with the same pathological type respond completely differently to the same drug, making it difficult for standardized treatment regimens to achieve expected efficacy.
· Complex Microenvironment: A Barrier to Drug Penetration
Stromal cells, immune cells, and the extracellular matrix within tumors form dense physical and biochemical barriers that not only hinder effective drug delivery but also weaken anti-tumor immune responses through immunosuppressive effects.
· Rapid Drug Resistance: The "Expiration Date" of Efficacy
Tumor cells possess strong adaptive evolutionary capabilities, rapidly undergoing epigenetic changes or gene mutations under drug pressure, causing targeted drugs to quickly lose efficacy after short-term remission—a major challenge in clinical treatment.

Classification, Characteristics, and Construction of Lung Cancer Models

In Vivo Models: These are model systems established by transplanting tumor tissues or cells into living animals, primarily including CDX (cell line-derived xenograft), PDX (patient-derived xenograft), GEMM (genetically engineered mouse model), and humanized mouse models. As a key bridge connecting in vitro experiments and clinical application, they can truly reflect tumor growth, metastasis, and drug response processes in a living physiological environment.

CDX Models

Definition
Tumor cell lines that have been long-term passaged in vitro (such as A549 lung cancer cells) are inoculated subcutaneously or orthotopically into immunodeficient mice (nude mice/NOD-SCID, etc.), allowing them to proliferate and form tumors in the host. This is currently the most mature and widely used basic in vivo model in drug development.
Technical Advantages and Limitations
Advantages include a short construction cycle (2-4 weeks), controllable costs, and strong experimental reproducibility. However, its limitations are also significant: long-term in vitro culture causes genotypic and phenotypic drift in cell lines, making it impossible to fully replicate patient tumor heterogeneity and the complexity of the tumor microenvironment.
Clinical Translation Value
Commonly used for preliminary in vivo efficacy screening of anti-tumor candidate drugs, exploration of drug resistance mechanisms, and drug dose optimization. It is also suitable for observing tumor growth kinetics and metastatic pathways, and provides basic data and experimental protocol references for subsequent more complex PDX model research.

PDX Models

Definition
A model established by directly transplanting fresh patient tumor tissue into immunodeficient mice. It fully preserves the genetic characteristics and microenvironment of the primary tumor and is a key bridge connecting clinical and basic research.
· Essential Feature: Human Tissue Xenograft
Unlike traditional cell line transplantation, PDX directly originates from patient surgical or biopsy samples, maximally simulating the growth pattern and heterogeneity of human tumors.
Clinical Value · Industry Gold Standard
· Most Reliable in Predicting Drug Efficacy
Recognized as the "gold standard" model for predicting clinical drug responses, with results highly correlated with real patient responses, effectively reducing the clinical failure rate of new drug development.
· Passageable and Sample Preservation
Successfully tumor-forming tissues can be stably passaged among mice, forming a "living biobank" that provides continuous and stable experimental materials for subsequent drug resistance mechanism research and combination drug screening.
Challenges · Application Limitations
· Long Cycle and High Cost
Model establishment typically takes 3-6 months, with a single case cost as high as 70,000. This high threshold limits its widespread application in large-scale drug screening.
· Lack of Human Immune System
Constructed on immunodeficient mice, there are no functional T/B lymphocytes in vivo. Therefore, this model cannot be used to evaluate the efficacy of novel immunotherapeutic drugs such as immune checkpoint inhibitors.

Genetically Engineered Mouse Models (GEMM)

Definition
Through cutting-edge gene editing technologies (such as CRISPR/Cas9), specific lung cancer driver gene mutations (such as KRAS, TP53) are precisely introduced into the mouse germline genome, allowing them to undergo a multi-stage evolutionary process in vivo highly similar to human lung cancer, spontaneously forming lung adenocarcinoma or squamous cell carcinoma. This model breaks through the limitations of traditional transplanted tumor models and is currently the only animal model that can simulate the entire natural process of lung cancer from precancerous lesions to invasive tumors.
Research Value: Reproducing Pathology and Immune Microenvironment
Capable of fully simulating the natural occurrence, development, and metastasis of tumors in vivo; at the same time, it retains a complete murine immune system, making it the "gold standard" model for studying tumor-host immune interactions and evaluating the efficacy and mechanisms of novel therapies such as immune checkpoint inhibitors.
Technical Challenges: The Double Barrier of Time and Cost
The model construction cycle is lengthy, with tumor observation typically requiring 6-12 months; and the construction cost per strain is high. In addition, the genetic background of inbred mice is relatively uniform, making it difficult to fully reproduce the highly heterogeneous gene mutation spectrum and tumor microenvironment characteristics of human lung cancer patients.
Clinical Translation Significance
GEMM models have become a key bridge connecting basic medical discoveries and clinical treatment development. Despite the difficulties in construction and long cycles, they have irreplaceable unique advantages in validating oncogene functions, screening targeted drugs, and exploring combination therapy strategies, providing a solid in vivo research platform for breakthroughs in precision medicine for lung cancer.

Humanized Mouse Models

Definition
· Immunodeficient Mice + Human Immune Reconstitution: The Key Foundation for Building "Humanized PDX Models"
By transplanting human hematopoietic stem cells or peripheral blood lymphocytes into severely immunodeficient mice, a functional human immune system is reconstituted in the mice. This technology is often deeply combined with PDX (patient-derived xenograft) models, solving the core problem of traditional PDX models lacking a human immune microenvironment.
Clinical Translation · Unique Value
· The Only In Vivo Platform for Studying Human-Human Interactions: The "Gold Standard" for Immunotherapy Drug Development
This model can truly simulate the dynamic in vivo interactions between human tumor cells and immune cells. It plays an irreplaceable role in the screening, efficacy evaluation, and mechanism research of immunotherapeutic drugs such as PD-1/PD-L1 inhibitors and CAR-T therapies. It can effectively predict the potential efficacy of drugs in humans, significantly reducing the risk of clinical development failure.
Current Limitations · Urgent Breakthroughs Needed
· High Technical Threshold and Expensive: Uniformity of Immune Reconstitution Needs Optimization

Model construction involves complex hematopoietic stem cell transplantation and long-term reconstitution processes, with high technical difficulty and long experimental cycles. At the same time, there are differences in immune reconstitution levels among individual mice, which may affect the stability of experimental data. In addition, the high construction and maintenance costs limit its widespread application in large-scale drug screening, which is currently a major challenge in preclinical research.

Introduction to Subcutaneous and Orthotopic Lung Tumor Models

Subcutaneous Tumor Models

Small Cell Lung Cancer: NCI-H524, NCI-H446, NCI-H69
Non-Small Cell Lung Cancer: PC-9, NCI-H1975, NCI-H358

Power your preclinical lung cancer studies! VITRO BIOTECH provides a large series of lung cancer cell lines. Click to order>>

Orthotopic Tumor Models

Non-Small Cell Lung Cancer: NCI-H1975-LUC

Drive breakthroughs in lung cancer research! Luciferase cell lines enable visible and quantifiable lung cancer studies. Learn more>>